<DOC>
	<DOCNO>NCT00872014</DOCNO>
	<brief_summary>The purpose study determine whether AMG 386 , combination Sorafenib , effective treatment advance inoperable Hepatocellular cancer subject receive prior systemic therapy except surgery locoregional therapy . Disease status disease progression assess every 8 week . Subjects remain treatment : progressive disease RECIST criterion ; clinical progression ; death loss follow-up ; withdrawal inform consent .</brief_summary>
	<brief_title>A Study Effectiveness Safety AMG 386 Sorafenib Treat Advanced Inoperable Hepatocellular Cancer</brief_title>
	<detailed_description>The primary objective evaluate efficacy AMG 386 combination sorafenib measure progression free survival ( PFS ) rate 4 month subject advance inoperable hepatocellular carcinoma ( HCC ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm advanced inoperable HCC ChildPugh A liver function score Measurable disease least one unidimensionally measurable lesion per RECIST 1.0 guideline modification Adequate organ hematological function Men woman great equal 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 2 less Subject eligible liver transplant per investigator discretion Any previous systemic chemotherapy HCC History arterial venous thromboembolism within 12 month prior enrollment History clinically significant bleeding within 6 month prior enrollment History central nervous system metastases Clinically significant cardiovascular disease within 12 month Uncontrolled hypertension Subjects history prior malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>